Diploma (LON:DPLM) Given Buy Rating at Deutsche Bank Aktiengesellschaft

Diploma (LON:DPLMGet Free Report)‘s stock had its “buy” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a research note issued on Friday,Digital Look reports. They presently have a GBX 5,100 ($64.21) price target on the stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 14.50% from the stock’s previous close.

Separately, Shore Capital cut shares of Diploma to a “hold” rating in a report on Tuesday.

View Our Latest Report on Diploma

Diploma Stock Up 5.5 %

Shares of DPLM traded up GBX 232 ($2.92) during midday trading on Friday, reaching GBX 4,454 ($56.07). The stock had a trading volume of 1,318,836 shares, compared to its average volume of 381,118. The company has a market cap of £5.97 billion, a price-to-earnings ratio of 5,179.07, a PEG ratio of 2.82 and a beta of 0.75. The company’s fifty day simple moving average is GBX 4,384.83 and its two-hundred day simple moving average is GBX 4,265.19. The company has a debt-to-equity ratio of 45.69, a current ratio of 2.27 and a quick ratio of 0.80. Diploma has a 1-year low of GBX 3,200 ($40.29) and a 1-year high of GBX 4,653 ($58.58).

Insider Activity

In other Diploma news, insider Johnny Thomson sold 26,794 shares of Diploma stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of GBX 4,536 ($57.11), for a total value of £1,215,375.84 ($1,530,121.92). Corporate insiders own 0.52% of the company’s stock.

About Diploma

(Get Free Report)

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.

Further Reading

Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.